What Johnson & Johnson's 8-K filings say: 3 filings, latest Oct 13, 2026
Johnson & Johnson filed its latest 8-K with the SEC on Oct 13, 2026. It discusses acquisition completed, product launch and restructuring.
Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API
What changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.- Filed
- Oct 13, 2026
- Filings
- 3
- Signals
- 11
Source: Autobound Signal API · 86 signals tracked for Johnson & Johnson · updated
8-K · latest 9
What Johnson & Johnson's 8-K filings say
- SEC EDGAR
8-K
Filed · 5 signals
Taubert's retirement brings new leadership overseeing more than $16 billion in quarterly pharmaceutical sales.
J&J recorded $181 million in restructuring expenses in Q3 2026, progressing a broader $650M-$750M supply chain restructuring program primarily exiting Innovative Medicine manufacturing locations through 2029.
$181M
restructuring expenses in third-quarter 2026
Johnson & Johnson Completes Acquisition of Firefly Bio to Expand Oncology Pipeline
The acquisition closes and integrates Firefly Bio into JNJ's Innovative Medicine business, creating near-term integration requirements across R&D, clinical systems, and supply chain infrastructure.
Firefly Bio, Inc.
FDA Grants Market Authorization for OTTAVA Soft Tissue Robotic Surgical System
JNJ received U.S. FDA market authorization for OTTAVA, marking commercial launch readiness for its table-integrated robotic surgery system and driving operational rollout across hospital networks.
surgical roboticsOTTAVA Robotic Surgical System
- SEC EDGAR
8-K
Filed · 3 signals
- SEC EDGAR
8-K
Filed · 3 signals
Johnson & Johnson completes acquisition of Firefly Bio, lowering 2026 margin guidance by ~150 bps.
The completed acquisition of Firefly Bio, combined with a new collaboration, will trigger post-merger integration and is projected to reduce 2026 adjusted pre-tax operating margin by approximately 150 basis points.
Firefly Bio, Inc.
The acquisition of Firefly Bio and a new collaboration with Sail Biomedicines will significantly impact short-term profitability, reducing 2026 adjusted EPS by $0.64.
Firefly Bio, Inc.Sail Biomedicines
The acquisition and strategic collaboration will reduce 2026 adjusted pre-tax operating margin by approximately 150 basis points and EPS by $0.64, indicating significant investment and integration costs.
Firefly Bio, Inc.Sail Biomedicines
Showing 9 of 11 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Johnson & Johnson with the Signal API
One POST /v1/companies/enrich call with jnj.com returns Johnson & Johnson 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","signal_types":["sec-8k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.
Same industry
8-K at related companies
Questions about Johnson & Johnson 8-K
When did Johnson & Johnson file its latest 8-K?
What did Johnson & Johnson disclose in its latest 8-K?
Where can I read Johnson & Johnson's 8-K filing?
Page updated , the date of the newest row on this page.
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .